<DOC>
	<DOCNO>NCT00598624</DOCNO>
	<brief_summary>This multicentric , non-randomized , non-controlled open-label phase II trial evaluate safety efficacy treosulfan combination regimen fludarabine condition therapy prior allogeneic stem cell transplantation ( SCT ) patient haematological malignancy . The aim demonstrate clinical benefit compare historical data intravenous busulfan ( BusulfexTM , BusilvexTM ) , drug far registered indication condition allogeneic stem cell transplantation .</brief_summary>
	<brief_title>Clinical Trial Evaluate Safety Efficacy Treosulfan Based Conditioning Prior Allogeneic Haematopoietic Stem Cell Transplantation ( HSCT )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Patients haematological malignancy , accord WHO classification , : acute myeloid leukaemia AML CR1 except `` lowrisk case '' define ( 15 ; 17 ) , ( 8 ; 21 ) , inv 16 normal cytogenetics diagnosis FLT3ITD negative NPM1 positive , high risk clinical criterion AML beyond CR1 acute lymphoblast leukaemia ALL CR1 `` high risk '' define cytogenetics ( 9 ; 22 ) , ( 4 ; 11 ) persistence minimal residual disease ( MRD ) ALL beyond CR1 chronic myeloid leukaemia CML chronic phase ( CP ) accelerate phase ( AP ) intolerant/not responsive TKinhibitors myeloproliferative disorder MPD myelodysplastic syndrome MDS intermediate high risk International Prognostic Scoring System ( IPSS ) diffuse large cell lymphoma DLCL chemosensitive relapse beyond CR1 lymphoblastic Burkitt lymphoma chemosensitive relapse beyond CR1 mantle cell lymphoma MCL chemosensitive relapse beyond CR1 follicular lymphoma FCL chemosensitive relapse beyond CR2 Hodgkin lymphoma HD chemosensitive relapse beyond CR1 chronic lymphocytic leukaemia CLL `` poor risk '' CR1 chemosensitive relapse CLL relapse high dose chemotherapy Tcell non Hodgkin lymphoma TNHL CR1 beyond multiple myeloma MM high risk cytogenetics ISS stage 3 CR1 follow high dose chemotherapy MM relapse/progression except refractory disease 2 . Availability HLAidentical sibling donor ( MRD ) HLAidentical unrelated donor ( MUD ) HLAidentity define follow marker : A , B , DRB1 , DQB1 single double Cord Blood unit ( CB ) least 4 6 HLAmatching follow marker : A , B DRB . A ) identity 2 CB unit recipient ; B ) Two identical CB unit one two mismatch recipient ; C ) Two CB unit one mismatch two mismatch recipient . We prefer mismatch either class I class II antigens ; avoid mismatch concern class I II together . 3 . Target graft size ( unmanipulated , preferably cryopreserved ) bone marrow : 2 10 x 106 CD34+ cells/kg BW recipient &gt; 2 x 108 nucleated cells/kg BW recipient peripheral blood : 4 10 x 106 CD34+ cells/kg BW recipient 4 . Age &gt; 18 &lt; 70 year 5 . Karnofsky Index &gt; 80 % 6 . Adequate contraception female patient childbearing potential 7 . Written inform consent 1 . Secondary malignancy 2 . Previous allogeneic transplantation 3 . Hematopoietic cell transplantationspecific comorbidity index &gt; 4 ( HCTCI Sorror et al , Appendix M ) 4 . Known manifested malignant involvement CNS 5 . Active infectious disease 6 . HIV positivity active hepatitis infection 7 . Impaired liver function ( Bilirubin &gt; upper normal limit ; Transaminases &gt; 3.0 x upper normal limit ) 8 . Impaired renal function ( Creatinineclearance &lt; 60 ml/min ; Serum Creatinine &gt; 1.5 x upper normal limit ) . 9 . Pleural effusion ascites &gt; 1.0 L 10 . Pregnancy lactation 11 . Known hypersensitivity treosulfan and/or fludarabine 12 . Participation another experimental drug trial within 4 week day 6 13 . Noncooperative behaviour noncompliance 14 . Psychiatric disease condition might impair ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>